SAM
ENTA icon

Smartleaf Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Smartleaf Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24K Sell
184
-226
-55% -$3.03K ﹤0.01% 2929
2025
Q4 		$6.52K Hold
410
– – ﹤0.01% 2595
2025
Q3 		$6.21K Buy
410
+339
+477% +$2.71K ﹤0.01% 2302
2025
Q2 		$532 Sell
71
-363
-84% -$2.18K ﹤0.01% 2575
2025
Q1 		$2.48K Buy
+434
New +$2.68K ﹤0.01% 2415
2024
Q4 		– Sell
-157
Closed -$1.58K – 2950
2024
Q3 		$1.58K Buy
+157
New +$2.05K ﹤0.01% 2554

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Smartleaf Asset Management's ENTA Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Enanta Pharmaceuticals (ENTA) stake by 55% in Q1 2026, selling an estimated $3.03K and leaving 184 shares worth $2.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Smartleaf Asset Management first reported a position in ENTA in Q3 2024 and has held it in 6 quarters since. The position peaked at $6.52K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Smartleaf Asset Management held 184 shares of Enanta Pharmaceuticals worth $2.24K as of Q1 2026.
  • Smartleaf Asset Management sold 226 Enanta Pharmaceuticals shares in Q1 2026, an estimated $3.03K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2929 holding.
  • Smartleaf Asset Management first reported a position in Enanta Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Smartleaf Asset Management's Enanta Pharmaceuticals position peaked at $6.52K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.